Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

In "HS Biologics: IL-17 vs TNF Inhibition, Bimekizumab Tunnel Data, and Early Treatment," the panel explores how pathway differences and EADV data influence biologic selection and timing.

HS Biologics: IL-17 vs TNF Inhibition, Bimekizumab Tunnel Data, and Early Treatment

The panel is asked how TNF-alpha and IL-17 inhibitors differ in the inflammatory pathways they target and how they are used differently in HS. The panel explains that TNF inhibitors offer broader inhibition and are a strong choice with comorbid inflammatory bowel disease, but they require awareness of possible exacerbation of congestive heart failure or links to multiple sclerosis. For patients with draining tunnels, an IL-17 agent, particularly one covering IL-17F, may be preferable because IL-17F is highly enriched in the epithelium lining sinus tracts. Panelists describe favoring TNF inhibitors for nodular phenotypes. The panel adds that growing data suggest meaningful differences among the three biologics.

Attention then turns to bimekizumab data presented at EADV from the BE HEARD studies, which tracked draining tunnel counts over three years. The mean baseline count was roughly 3.8 to 4, and the three-year change was a decrease of more than three. The analyses were also stratified by disease duration and prior biologic use.

That leads to a case for treating earlier. The panel pushes back on reserving biologics for the worst cases, noting that the risks of a drug stay constant while the benefit shrinks over time, so the best risk-benefit ratio comes from early, aggressive treatment. When patients are separated by disease duration, the response rate cited roughly halves, from 46% to 23%, in longer-standing disease. Patients with longer disease still deserve treatment and can improve, but the needle moves more with earlier treatment. The panel suggests the data may support using biologics sooner, in milder disease, and potentially reducing comorbidities. Even when tunnels resolve, scarring remains in functional areas that need soft, pliable tissue, so early aggressive treatment is described as tissue sparing.

In "HS Long-Term Outcomes: Durable Response, Tunnel Regression, and Monitoring," the panel will examine longer-term secukinumab data and how clinicians monitor patients over time.

Videos

Pathway biology and new draining tunnel data shape how the panel positions TNF and IL-17 inhibitors. The discussion also makes the case that earlier treatment improves response and preserves functional tissue.

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

"HS Surgery: De-Roofing Alongside Biologic Therapy" takes up the question of how procedures fit into HS care alongside advanced therapy.

HS Surgery: De-Roofing Alongside Biologic Therapy

The panel is asked how it views surgical procedures such as de-roofing and whether they help with pain, drainage, and quality of life. The panel describes disease management as two parallel tracks. Medical management includes counseling and escalation to biologics or oral small molecules, while surgical intervention can run alongside it. The surgical conversation should be raised at every follow-up visit, particularly when draining tunnels or localized inflammation could be controlled by a de-roofing procedure. The panel notes that data now support performing these procedures, and even larger surgeries, while patients remain on therapy. For a time, whether to take patients on and off their biologic around surgery was a major open question. The paradigm has shifted to treating on drug, which has improved outcomes because inflammation stays controlled while the patient heals. Remaining on biologics throughout is considered safe and probably better for healing, with no breaks needed.

For listeners who do not perform de-roofing, the panel emphasizes that it requires little time or equipment. It requires willingness, and procedures can be as small or as extensive as a clinician is comfortable with, always within scope of practice. Anyone who can perform an excision or electrodessication and curettage can de-roof, because the tools and tissue planes are the same. Clinicians can stop and ask for help if they reach an area outside their comfort zone. For larger operations, regional HS surgery experts and referral centers can perform graft placements, while smaller de-roofings are handled in the department.

The panel also covers coding. De-roofing uses the same CPT codes as certain plastic surgery procedures, which are limited to three anatomic areas: axilla, inguinal region, and buttocks. For the chest or back, clinicians approximate the closest area.

Our next episode, "HS Biologics: IL-17 vs TNF Inhibition, Bimekizumab Tunnel Data, and Early Treatment," turns to how TNF and IL-17 inhibitors differ and what newly presented tunnel data suggest.

Medical and surgical management work in parallel in HS. The panel argues for treating through surgery on biologics and explains why de-roofing is within reach for community clinicians.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her various hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Pulmonology news in October 2026 was defined largely by the 

American College of Chest Physicians (CHEST) 2026 Annual Meeting

, held October 18-21 in Phoenix, Arizona, which supplied much of the month's clinical data. The month's most consequential regulatory story arrived October 30, when the US Food and Drug Administration (FDA) granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd; Inovio) to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP). It is the first plasmid DNA-based immunotherapy approved in the US. 

 In pulmonary vascular and interstitial lung disease, a risk-stratified analysis of the phase 3 ADVANCE OUTCOMES trial found that ralinepag reduced clinical worsening in pulmonary arterial hypertension, including among patients meeting low-risk criteria. A post hoc analysis of the phase 3 TETON-2 trial found fewer total progression events with inhaled treprostinil than placebo in idiopathic pulmonary fibrosis (126 vs 161; 

 =.003). In obstructive airway disease, tozorakimab improved patient-reported daily respiratory symptoms in the OBERON and TITANIA trials in COPD. An integrated SWIFT/AGILE analysis found that clinical remission with depemokimab at year 1 was associated with fewer asthma exacerbations in year 2. An ASPEN post hoc analysis linked patient-reported sputum color to neutrophil serine protease activity in bronchiectasis. HCPLive's on-site interviews also covered nalbuphine extended-release for IPF cough, AD109 in obstructive sleep apnea, and robotic bronchoscopy. 

Check out this October 2026 pulmonology month in review for full coverage of these stories and more.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd; Inovio) is a plasmid DNA-based immunotherapy that delivers 1 plasmid encoding HPV-6 and HPV-11 antigens and a second encoding interleukin-12. It is given intramuscularly with the CELLECTRA 5PSP electroporation device over a 9-week regimen. The FDA granted accelerated approval October 30, 2026, to reduce the frequency of surgical papilloma excisions in adults with RRP, based on the RRP-001 trial, in which 27% (7/26; 95% CI, 12%–48%) of patients with 3 or more surgeries in the prior 12 months had a complete response through 12 months of follow-up. RRP-001 had no control arm, and Inovio plans to submit a draft confirmatory trial protocol to the FDA by the end of 2026.

The CHEST 2026 Annual Meeting brought new data across interstitial lung disease, COPD, severe asthma, sleep medicine, and interventional pulmonology, including 3 late-breaking abstracts. In this edition of the HCPLive Five, investigators discuss nalbuphine extended-release for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in obstructive sleep apnea, and robotic bronchoscopy.

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag, an investigational once-daily oral prostacyclin receptor agonist, reduced the risk of clinical worsening by 55% vs placebo in the phase 3 ADVANCE OUTCOMES trial (HR, 0.45; 95% CI, 0.33–0.62; 

 <.0001). A CHEST 2026 subgroup analysis stratified participants by 3 noninvasive low-risk criteria: NT-proBNP below 300 pg/mL, 6-minute walk distance above 440 m, and WHO functional class I or II. Jean Elwing, MD, of the University of Cincinnati College of Medicine, said patients who met all 3 criteria still had fewer clinical worsening events with ralinepag. Those who met none had an HR of 0.60 with a confidence interval crossing 1.0. The FDA has accepted the new drug application with a PDUFA date of June 24, 2027.

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes

In SWIFT-1/-2, 29% of patients with type 2 asthma receiving twice-yearly depemokimab (Exdensur; GSK) achieved 4-component clinical remission at week 52, vs 23% with placebo. An integrated SWIFT/AGILE analysis presented at CHEST 2026 by Michael Wechsler, MD, found that 59% of patients in remission at year 1 remained in remission at year 2. Year 2 annualized exacerbation rates were 0.19 (95% CI, 0.12–0.29) among patients in remission at year 1 vs 0.69 (95% CI, 0.57–0.82) among those not in remission. Patients in remission at year 1 also showed greater improvement across all 3 secondary outcomes at year 2. The analysis is observational and shows association, not causation.

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA

Tozorakimab (AstraZeneca), an anti–IL-33 monoclonal antibody, 300 mg every 4 weeks improved Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total scores vs placebo at week 52 in both phase 3 OBERON and TITANIA trials. Improvements spanned the breathlessness, cough/sputum, and chest symptom domains, according to an analysis presented at CHEST 2026. Frank Sciurba, MD, of the University of Pittsburgh, said symptom benefit matters to patients independent of exacerbation risk reduction. In the primary population of former smokers, the trials previously showed 29% and 34% reductions in moderate and severe exacerbations, respectively. The FDA has accepted the biologics license application for COPD under Priority Review, with a PDUFA date anticipated in the first quarter of 2027.

Sputum Color Flags Severity in Bronchiectasis: James Chalmers, MBChB, PhD

A post hoc analysis of the phase 3 ASPEN trial, presented at CHEST 2026, found that patient-reported sputum color reflected neutrophil serine protease activity and overall disease activity in bronchiectasis. Participants rated sputum color daily on a 6-point scale in the Bronchiectasis Exacerbation and Symptom Tool diary. Greater baseline purulence was associated with higher sputum neutrophil counts, 

 positivity, exacerbation rates, and Bronchiectasis-Computed Tomography scores, as well as lower postbronchodilator percent predicted forced expiratory volume in 1 second. Brensocatib (Brinsupri) reduced neutrophil elastase activity across all sputum color categories. James Chalmers, MBChB, PhD, of the University of Oxford, said patients with mucoid sputum can still be inflamed and benefit, which is relevant to growing interest in treating earlier disease.

Inhaled Treprostinil After IPF Progression, With Steven Nathan, MD

A post hoc analysis of the phase 3 TETON-2 trial, presented at CHEST 2026, counted every disease progression event across 52 weeks instead of only the first. In total, 126 events occurred in 82 patients receiving inhaled treprostinil (Tyvaso; United Therapeutics) vs 161 events in 115 patients receiving placebo (

 =.003). The difference was driven mainly by relative declines of 10% or more in percent predicted forced vital capacity (54 vs 86 events) and concurrent IPF exacerbation with respiratory hospitalization (6 vs 18 events). Adjudicated respiratory hospitalizations were numerically more frequent with inhaled treprostinil (45 vs 34 events), and the number of patients with more than 1 event did not differ significantly (26 vs 36; 

 =.166). Steven D. Nathan, MD, of Inova and the University of Virginia, said the findings support continuing therapy after a first progression event. Inhaled treprostinil remains investigational for IPF, with FDA review of the supplemental new drug application expected to be complete in late April 2027.

Brooks A. Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis. HCPLive. October 30, 2026. 

https://www.hcplive.com/view/voceryq-gains-fda-accelerated-approval-for-recurrent-respiratory-papillomatosis

Derman C. HCPLive Five at CHEST 2026. HCPLive. October 30, 2026. 

https://www.hcplive.com/view/hcplive-five-chest-2026

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD. HCPLive. October 23, 2026. 

https://www.hcplive.com/view/ralinepag-cuts-pah-worsening-low-risk-patients-elwing

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes. HCPLive. October 21, 2026. 

https://www.hcplive.com/view/depemokimab-year-1-remission-linked-better-year-2-asthma-outcomes

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA. HCPLive. October 21, 2026. 

https://www.hcplive.com/view/tozorakimab-improves-daily-respiratory-symptoms-copd-oberon-titania

Sputum Color Flags Severity in Bronchiectasis: James Chalmers, MBChB, PhD. HCPLive. October 30, 2026. 

https://www.hcplive.com/view/sputum-color-flags-severity-bronchiectasis-chalmers

Nathan SD. Inhaled Treprostinil After IPF Progression, With Steven Nathan, MD. HCPLive. November 2, 2026. 

https://www.hcplive.com/view/inhaled-treprostinil-ipf-progression

Articles

October 2026 pulmonology highlights include FDA accelerated approval of Voceryq for recurrent respiratory papillomatosis and CHEST 2026 data.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

7 Pulmonology Headlines You Missed in October

Elevated cardiovascular inflammation (CVI) affects roughly 50% of US patients with 

 across the spectrum, potentially corresponding to HF severity through higher IL-6 and NT-proBNP.

Higher Cardiovascular Inflammation Prevalent Across All Heart Failure Subtypes

These data, a subanalysis of the POSEIDON study, were presented at the 

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

 in Phoenix, Arizona, by Marat Fudim, MD, an associate professor at Duke University Health and a member of the American Heart Association’s Heart Technology Advisory Group.

“The real reason this registry was put into place is because there is a cadre of clinical trials going on – a couple of these trials were halted and are going to be terminated because there was no apparent benefit to blocking IL-6 versus placebo,” Fudim told 

 in an exclusive interview. “Now this is very disappointing, but it does not mean that this registry has no value anymore. Quite the opposite: it shows that we may have lost the battle, but we have not lost the war.”

POSEIDON was a cross-sectional, global, real-world prevalence study spanning 317 sites in 18 countries. Patients were eligible if they had atherosclerotic cardiovascular disease (ASCVD) and/or HF, as well as serum creatinine in the medical chart within 24 months prior to signing of informed consent. Patients with a hospitalization of any kind within the last 60 days or clinical evidence or suspicion of active infection within the same period, among other criteria, were excluded.

The POSEIDON study ultimately enrolled 18,904 individuals, including 11,809 with HF and available hsCRP. Of these, 3714 had preserved ejection fraction (HFpEF), 2176 had mildly reduced EF (HFmrEF), and 5919 had reduced EF (HFrEF). Elevated hsCRP was found in 1442 patients with HFpEF, 830 with HFmrEF, and 2263 with HFrEF. In each subtype, patients with elevated hsCRP were more likely to be female and have chronic kidney disease (CKD), obesity, worse functional class, and higher NT-proBNP. These predictors were also consistent across HF subtypes, with the exception of body mass index (BMI).

In the present analysis, Fudim and colleagues brought a cohort of US-based patients from the POSEIDON study into the clinic for a singular study visit with a blood sample collection. A total of 810 patients were included in this substudy, and CVI risk was categorized as either low (hsCRP <2 mg/L) or high (hsCRP ≥2 mg/L). Of these patients, 315 had HFpEF, 94 had HFmrEF, and 392 had HFrEF.

Fudim and colleagues found that nearly 50% of patients across the HF spectrum had CVI risk: in the HFpEF group, 49% of patients had hsCRP ≥2 mg/L, while 55% in the HFmrEF group and 50% in the HFrEF group had hsCRP ≥2 mg/L. The team noted that these measures represented residual inflammatory risk persisting despite current management; additionally, CVI risk was numerically higher in the US cohort than in the global POSEIDON study. The team also recorded a potential association between hsCRP ≥2 mg/L and higher IL-6 and NT-proBNP across all HF phenotypes and risk subgroups.

Ultimately, Fudim and colleagues noted that CVI risk may potentially provide a link between inflammatory pathway activation and HF severity. They also noted that its frequent presence across all HF phenotypes could present an opportunity for further research into anti-inflammatory approaches to reducing cardiovascular risk.

“First of all, I would want to know if treatment of inflammation really results in better outcomes; we haven’t had many successful stories there,” Fudim said. “That’s A. B is whether the risk of CVI change over time in the same individuals. It would have been nice to longitudinally track and see if people change their risk over time, and then to also understand what it is that led to that risk reclassification. So, yes, longitudinal data would be amazing.”

Editors’ Note: Fudim reports disclosures with Alleviant, the American Heart Association, Bayer, Impulse Dynamics, Novo Nordisk, Summacor, and others.

Fudim M, Contreras J, Ibrahim H, et al. Prevalence of Cardiovascular Inflammation and Associated Patient Characteristics and Biomarker Profiles Across the Heart Failure Spectrum in the United States: Results From the POSEIDON Study. Presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, Phoenix, AZ. October 9-12, 2026.

Novo Nordisk A/S. Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) (POSEIDON). ClinicalTrials.gov Identifier: NCT06122961. Updated May 9, 2026. Accessed November 4, 2026. 

https://clinicaltrials.gov/study/NCT06122961?term=NCT06122961&rank=1

Lam CS, Contreras J, Darwesh R, et al. Prevalence and predictors of high inflammatory risk in heart failure subtypes: Findings from the Global Poseidon Study. European Journal of Heart Failure. Published online May 10, 2026. 

Marat Fudim, MD, discusses his analysis of a US cohort from the POSEIDON study, which found a potential association between CVI and HF severity.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

’s team is providing on-site coverage of the 

2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) International COPD Conference

, held November 5 to 6 at the Pennsylvania Convention Center in Philadelphia, featuring a presentation of the 2027 GOLD Report and interviews with leaders in 

chronic obstructive pulmonary disease (COPD)

Now in its 11th year, the meeting is co-hosted by the Temple Lung Center and co-sponsored by GOLD, with Gerard Criner, MD, director of the Temple Lung Center, opening and closing each day.²,³ It offers up to 8.5 

™ through Integrity CE, LLC, with sessions available in person and virtually.¹

Over the course of this 2-day meeting, pulmonologists, primary care clinicians, advanced practice providers, pharmacists, and respiratory therapists will convene to review the latest GOLD strategy, emerging therapeutic targets, and approaches to earlier diagnosis and exacerbation prevention.

What to Expect at GOLD 2026 in Philadelphia:

This year’s program opens with COPD Essentials, a pre-conference course on translating the GOLD strategy into practice, followed by 7 main sessions, CME symposia, and industry product theaters.² Topics span mucus plugging, exacerbation definitions, multimorbidity, proactive diagnosis, neutrophilic inflammation, type 2 inflammation, and alarmin-targeted therapy.²

 will be on-site throughout the conference, providing exclusive interviews with COPD leaders, coverage of notable sessions, and reporting on the latest clinical insights shared during the meeting.

 Shawn Aaron, MD, reviews initial therapy and early management strategies under the GOLD ABE framework (Thursday, November 5)

 David MG Halpin, MA, DPhil, MBBS, FRCP, FERS, discusses how to choose the best inhaler for each patient, following a device review from Ed Portillo, PharmD (Thursday, November 5)

 Criner covers advanced supportive therapies and respiratory support in COPD (Thursday, November 5)

 Dave Singh, MD, addresses disease stability and how clinicians can recognize when additional therapy is needed (Thursday, November 5)

Among the many sessions on this year’s agenda, the following offer practical updates for clinicians attending the conference.

Role of Mucus in Disease Progression in COPD

Thursday, November 5 • 2:05–3:20 PM ET • Terrace Ballroom I

 Moderated by Criner and María Montes de Oca, MD, PhD, this session examines the burden of mucus plugging in moderate to severe COPD, the role of type 2 cytokines in mucus plug formation, and precision approaches to targeting mucus. Speakers include Emily Wan, MD, MPH; Monica Kraft, MD; and Mario Castro, MD, MPH.

Thursday, November 5 • 3:45–5:05 PM ET • Terrace Ballroom I

 Jadwiga A. Wedzicha, MD, moderates a session on why updated exacerbation definitions are needed, whether the Rome proposal works in practice, and which tests to order in the emergency department or hospital. Faculty include Leonardo M. Fabbri, MD, FERS; Bartolome R. Celli, MD; and Carlos A. Camargo, MD, DrPH.

Multimorbidity in Patients With COPD: What Can We Do About It?

Thursday, November 5 • 6:25–7:40 PM ET • Terrace Ballroom I

 Fabbri and Celli lead a look at multimorbidity in COPD, including the 5 M’s framework and the cardiovascular and respiratory clusters. Faculty include Nathaniel Hawkins, MBChB, MD, MPH, and Frits Franssen, MD, PhD.

Moving to a Proactive Approach to the Diagnosis, Assessment and Management of COPD

Friday, November 6 • 8:10–9:45 AM ET • Terrace Ballroom I

 Moderated by Claus Vogelmeier, MD, and Alvar Agusti, MD, this session addresses the underdiagnosis gap in COPD, case-finding in the community, the case for preventing every exacerbation, and how to define disease stability. Speakers include Agusti, Aaron, Halpin, and Singh.

Targeting Neutrophilic Inflammation in COPD

Friday, November 6 • 11:05 AM–12:20 PM ET • Terrace Ballroom I

 Stephen Rennard, MD; Charlie Strange, MD; and James D. Chalmers, MBChB, PhD, will review the role of neutrophilic inflammation in COPD, elastase inhibition, and dipeptidyl peptidase 1 (DPP1) inhibition in bronchiectasis, including in patients with COPD. Robert A. Sandhaus, MD, PhD, and Montes de Oca moderate.

2027 GOLD Report and Review/COPD Call to Action

Friday, November 6 • 1:35–2:25 PM ET • Terrace Ballroom I

 Vogelmeier and Agusti will present the 2027 GOLD Report, followed by audience questions. Obianuju Ozoh, MBBS, MSc, and Jinping Zheng, MD, moderate.

Targeting Pathways in COPD: A Glimpse Into the Future?

Friday, November 6 • 3:45–5:00 PM ET • Terrace Ballroom I

 Moderated by Singh, this session explores airway immunology in the biologic era, lessons from type 2 inflammation in asthma, and alarmin-targeted approaches to epithelial health. Faculty include Lena Uller, PhD, MSc; Guy Brusselle, MD, PhD, FERS; and Wedzicha.

The HCPLive team will provide ongoing coverage from Philadelphia, including session highlights, expert interviews, and key clinical takeaways from the 2026 GOLD International COPD Conference.

Editor’s note: This summary was created with the help of AI tools.

Integrity Continuing Education. 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) International Chronic Obstructive Pulmonary Disease (COPD) Conference. eMedEvents. Accessed November 4, 2026. 

https://www.emedevents.com/medical-hybrid-events-2026/2026-global-initiative-for-chronic-obstructive-lung-disease-gold-international-chronic-obstructive-pulmonary-disease-copd-conference

2026 GOLD International COPD Conference agenda. Accessed November 4, 2026.

Temple Health. Temple co-hosts 2024 GOLD International COPD Conference. Accessed November 4, 2026. 

https://www.templehealth.org/about/news/temple-co-hosts-2024-gold-international-copd-conference

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

Conference Preview: 2026 GOLD International COPD Conference

Bradley Dixon, MD, discusses VALIANT+VALE data showing sustained proteinuria reduction and stable eGFR through 76 weeks in adolescents with C3G or IC-MPGN.



Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Chronic Kidney Disease

Could Earlier Complement Inhibition Preserve Kidney Function in C3G?

Pegcetacoplan Sustains Proteinuria Reduction at 76 Weeks in Adolescents

Tobias Uhe, MD, is a specialist in internal medicine and cardiology and a senior physician at the University of Leipzig.

Tobias Uhe, MD, discusses the results of the Find-AF 2 Watch trial, examining 2 different smart watches as AF monitors in patients with a recent ischemic stroke.

Arrhythmia

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Smart Watches Detect Atrial Fibrillation After Stroke, Sensitivity Depends Episode Duration

Gregory Bensch, MD, and Bay Area allergy clinicians discuss where ruxolitinib, tapinarof, and roflumilast creams fit after topical corticosteroids.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

October 2026 allergy news: FDA approvals for berotralstat pellets and remibrutinib, RAPIDe-3 data in HAE, alpha-gal syndrome, and Viaskin Peanut Patch.


Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

7 Allergy Headlines You Missed in October 2026

Shakar Kutal is a doctoral researcher at Helsinki University Hospital.

Shakar Kutal, a doctoral researcher at Helsinki University, discusses his study evaluating the role of dietary factors in early-onset CIS among young adults.

Adherence to Plant-Based Mediterranean Diet May Reduce Cryptogenic Stroke Risk

Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Oral vs Injectable: How Patients Weigh Systemic Psoriasis Options

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

REMODEL adds esophageal function to the conversation about EoE disease control. Distensibility and esophageal caliber may reveal clinically meaningful changes that symptoms, histology, and visual endoscopy alone cannot fully capture.

Applying REMODEL Findings to Esophageal Function in EoE

Alexa B. Kimball, MD, MPH, serves as a professor of dermatology at Harvard Medical School as well as president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center. 

Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Q&A: Tulisokibart Safety Findings, IBD Overlap, and Phase 3 Questions in HS

Successful EoE treatment requires more than symptom relief. Symptoms, endoscopic improvement, and histologic control provide complementary measures of response while therapeutic mechanisms target inflammation in different ways.

Latest News

HS Biologics: IL-17 vs TNF Inhibition, Bimekizumab Tunnel Data, and Early Treatment

HS Surgery: De-Roofing Alongside Biologic Therapy

7 Pulmonology Headlines You Missed in October

Higher Cardiovascular Inflammation Prevalent Across All Heart Failure Subtypes

Conference Preview: 2026 GOLD International COPD Conference